Journal of Medical Clinical Case Reports,
Год журнала:
2023,
Номер
unknown
Опубликована: Сен. 1, 2023
According
to
World
Health
Organisation
data,
cancer
is
one
of
the
most
influential
diseases
that
goes
head
with
heart
in
ranking
causes
death,
causing
approximately
10
million
deaths
annually
and
accounting
for
20%
all
deaths.
Lung
a
leading
cause
cancer-related
globally
both
men
women.
In
some
pre-clinical
studies
cell
line
vitro
experiments,
results
have
been
obtained
Aloe
Vera
Extract
(AVE)
from
vera
plant
Cannabindiol
(CBD)
Cannabis
sativa
may
anticancer
effect
against
cancer,
but
more
analysis
required
reliability
these
results.
this
study,
cytotoxic
apoptotic
effects
AVE
CBD
human
lung
(A549
BEAS)
cells
were
studied
multifaceted
manner.
Diagnosis
disease
15%
early
stage
85%
late
or
metastatic
stage.
Therefore,
despite
use
targeted
drugs
today,
5-year
survival
rate
patients
can
only
be
5-10%.
on
A549
healthy
normal
BEAS-2B
versatile
comparative
Cytotoxic
was
evaluated
by
xCELLigence
RTCA
System
AnnexinV-FITC/PI
Apoptosis
Assay
Flow
Cytometry.
current
investigation,
we
discovered
might
incite
relative
higher
ratio
death
(A549)
than
non-cancer
epithelial
BEAS-2B,
which
achieved
through
regulating
mitochondrial
metabolism.
summary,
our
research
under
Patent
submission
shows
potential
develop
into
potent
new
anti-lung
drug.
Journal of Cannabis Research,
Год журнала:
2025,
Номер
7(1)
Опубликована: Янв. 4, 2025
Abstract
Background
Differences
in
cannabinoid
metabolism
and
patient
responses
can
arise
even
with
equivalent
doses
formulations.
Genetic
polymorphisms
genes
responsible
for
medications
that
alter
CYP450
pathways
of
cannabinoids
may
account
some
this
variability.
Materials
methods
A
retrospective
chart
review
was
conducted
on
a
cohort
unselected
patients
who
had
previously
completed
pharmacogenomic
testing
reported
oral
cannabis
use,
as
defined
“oral”
or
“by
mouth”
route
administration.
The
objective
to
identify
atypical
variants
formulate
hypothesis
how
these
variables
influence
the
Tetrahydrocannabinol
(THC)
Cannabidiol
(CBD).
Results
Oral
use
confirmed
71
patients,
an
average
age
68.5
years,
primarily
white
women.
Of
10
no
variants;
31
CYP2C9;
37
CYP2C19;
6
CYP3A4;
15
CYP3A5.
5
were
taking
could
interact
THC,
8
CBD.
Conclusion
results
study
reveal
spectrum
hypothesized
alterations
THC
CBD
due
genetic
medications.
absence
published
clinical
outcomes
field
renders
it
challenging
estimate
significance
findings.
Until
such
data
become
available,
clinicians
should
remain
aware
possibility
impact
patients’
Current Issues in Molecular Biology,
Год журнала:
2024,
Номер
46(5), С. 4379 - 4402
Опубликована: Май 6, 2024
Alzheimer’s
disease
(AD)
is
a
progressive
neurodegenerative
and
the
most
common
form
of
dementia
globally.
Although
direct
cause
AD
remains
under
debate,
neuroinflammation
oxidative
stress
are
critical
components
in
its
pathogenesis
progression.
As
result,
compounds
like
cannabidiol
(CBD)
being
increasingly
investigated
for
their
ability
to
provide
antioxidant
anti-inflammatory
neuroprotection.
CBD
primary
non-psychotropic
phytocannabinoid
derived
from
Cannabis
sativa.
It
has
been
found
beneficial
outcomes
variety
medical
conditions
gaining
increasing
attention
potential
therapeutic
application
AD.
not
psychoactive
lipophilic
nature
allows
rapid
distribution
throughout
body,
including
across
blood–brain
barrier
(BBB).
also
possesses
anti-inflammatory,
antioxidant,
neuroprotective
properties,
making
it
viable
candidate
treatment.
This
review
outlines
CBD’s
mechanism
action,
role
AD,
effectiveness
limitations
preclinical
models
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(11), С. 5749 - 5749
Опубликована: Май 25, 2024
Neurological
disorders
present
a
wide
range
of
symptoms
and
challenges
in
diagnosis
treatment.
Cannabis
sativa,
with
its
diverse
chemical
composition,
offers
potential
therapeutic
benefits
due
to
anticonvulsive,
analgesic,
anti-inflammatory,
neuroprotective
properties.
Beyond
cannabinoids,
cannabis
contains
terpenes
polyphenols,
which
synergistically
enhance
pharmacological
effects.
Various
administration
routes,
including
vaporization,
oral
ingestion,
sublingual,
rectal,
provide
flexibility
treatment
delivery.
This
review
shows
the
efficacy
managing
neurological
such
as
epilepsy,
neurodegenerative
diseases,
neurodevelopmental
disorders,
psychiatric
painful
pathologies.
Drawing
from
surveys,
patient
studies,
clinical
trials,
it
highlights
alleviating
symptoms,
slowing
disease
progression,
improving
overall
quality
life
for
patients.
Understanding
mechanisms
can
open
up
possibilities
using
this
plant
individual
needs.
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 6, 2025
Cannabinoids
have
gained
increasing
attention
for
their
therapeutic
potential
in
treating
several
neurological
conditions,
including
neurodegenerative
diseases,
chronic
pain,
and
epilepsy.
This
review
aims
to
assess
the
current
clinical
trials
investigating
cannabinoids,
primarily
Tetrahydrocannabinol
Cannabidiol,
disorders.
will
aim
highlight
efficacy,
safety,
outcome
measures
used
these
trials.
Clinical
were
identified
using
ClinicalTrials.gov,
focusing
on
studies
that
examined
effects
of
cannabinoids
conditions.
All
fulfilled
following
criteria
included:
Phase
1-4,
focused
as
primary
intervention,
measured
relevant
outcomes
such
pain
relief,
cognitive
function,
or
spasticity
reduction.
Data
interventions,
secondary
outcomes,
trial
phases
extracted
analysed.
A
total
47
identified,
different
The
most
frequently
studied
conditions
Multiple
Sclerosis,
Fibromyalgia,
Parkinson's
Disease.
Most
2,
with
management,
spasticity,
function.
Secondary
included
safety
tolerability
measures.
highlights
broad
neurology,
promising
results
symptom
management
like
Sclerosis
Fibromyalgia.
However,
lack
standardized
study
protocols,
dosing,
presents
challenges
broader
implementation.
clinicatrials.gov.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(6), С. 1540 - 1540
Опубликована: Март 7, 2024
In
this
overview,
we
seek
to
appraise
recent
experimental
and
observational
studies
investigating
THC
its
potential
role
as
adjunctive
therapy
in
various
medical
illnesses.
Recent
clinical
trials
are
suggestive
of
the
diverse
pharmacologic
potentials
for
but
suffer
from
small
sample
sizes,
short
study
duration,
failure
address
tolerance,
little
dose
variation,
ill-defined
outcome
measures,
identify
and/or
evaluate
confounds,
all
which
may
constitute
significant
threats
validity
most
trials.
However,
existing
work
underscores
therapeutic
value
and,
at
same
time,
calls
attention
critical
need
better-designed
protocols
fully
explore
demonstrate
safety
efficacy.
general
sense,
present
brief
review
illuminates
some
intriguing
findings
about
THC,
along
with
basic
research
that
supports
those
findings.
The
intent
is
highlight
generic
weaknesses
randomized
controlled
trial
literature
importantly,
provide
guidance
improved
research.
Molecules,
Год журнала:
2025,
Номер
30(4), С. 918 - 918
Опубликована: Фев. 17, 2025
The
reason
why
young
people
taking
concomitantly
cannabis
(THC)
and
ethanol
(EtOH)
are
more
prone
to
stroke
is
underresearched.
To
investigate
whether
an
underlying
mechanism
of
increased
brain
damage
could
be
impaired
mitochondrial
function,
this
experiment
determined
the
acute
effects
EtOH,
both
alone
associated
with
THC,
on
respiration
oxidative
stress
(hydrogen
peroxide
H2O2)
(11
weeks)
middle-aged
(45
in
rats,
using
a
high-resolution
oxygraph
(Oxygraph-2K,
Oroboros
instruments).
In
brains,
EtOH
decreased
by
-51.76
±
2.60%
(from
32.76
3.82
17.41
1.42
pmol/s/mL,
p
<
0.0001).
45-week-old
decrease
was
lesser,
but
still
significant
-36.0
2.80%
30.73
7.72
20.59
5.48
Concomitant
THC
aggravated
decreases
at
11
weeks
(-86.86
1.74%,
0.0001)
45
(-73.95
3.69%,
Such
additional
injury
enhanced
brains
(p
0.01).
H2O2
production
similar
age
groups
(1.0
0.2
versus
1.1
0.08
pmol
O2/s/mL)
not
modified
addition.
conclusion,
significantly
impairs
concomitant
further
aggravates
such
damage,
particularly
brains.
These
data
support
hypothesis
that
dysfunction
might
participate
occurrence
urge
for
better
prevention
against
addictions
adolescents.
Current Issues in Molecular Biology,
Год журнала:
2025,
Номер
47(4), С. 230 - 230
Опубликована: Март 27, 2025
Fibromyalgia
is
a
chronic
disease
marked
by
extensive
musculoskeletal
pain,
persistent
fatigue,
and
cognitive
impairments.
Despite
its
high
prevalence,
the
underlying
pathological
mechanisms
of
fibromyalgia
are
still
not
fully
elucidated.
Emerging
research
has
identified
endocannabinoid
system
as
an
essential
factor
in
modulating
pain
other
symptoms
related
to
fibromyalgia.
The
plays
key
role
many
physiological
processes
such
perception,
mood
regulation,
inflammation.
This
review
provides
powerful
analysis
principal
aspects
examines
evidence
regarding
involvement
this
condition,
focusing
on
influence
modulation.
Moreover,
dysregulation
patients
will
be
examined,
with
assessment
how
variations
levels
receptor
activity
may
contribute
clinical
manifestations
condition.
A
better
knowledge
could
lead
development
novel
strategies
for
managing
